Compass Pathways (NASDAQ:CMPS) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Compass Pathways (NASDAQ:CMPS) from a strong sell rating to a sell rating in a report issued on Sunday.

Other equities analysts have also recently issued reports about the stock. Raymond James Financial reissued a “buy” rating on shares of Compass Pathways in a research report on Friday, May 22nd. Maxim Group upped their price objective on shares of Compass Pathways from $12.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, May 15th. Evercore raised Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 price objective on the stock in a research note on Wednesday, July 8th. Royal Bank Of Canada reduced their target price on Compass Pathways from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Finally, HC Wainwright decreased their target price on Compass Pathways from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $23.36.

Compass Pathways Price Performance

Compass Pathways stock opened at $13.45 on Friday. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $1.86 billion, a P/E ratio of -2.91 and a beta of 2.50. The business has a 50-day moving average of $12.63 and a 200-day moving average of $9.58. Compass Pathways has a 1 year low of $3.97 and a 1 year high of $15.40.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($1.49). On average, equities analysts anticipate that Compass Pathways will post -1.26 EPS for the current year.

Institutional Investors Weigh In On Compass Pathways

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC lifted its holdings in shares of Compass Pathways by 67.7% in the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after purchasing an additional 1,920 shares in the last quarter. Persistent Asset Partners Ltd bought a new position in shares of Compass Pathways during the 4th quarter worth approximately $38,000. Parallel Advisors LLC grew its stake in shares of Compass Pathways by 8,450.6% during the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after acquiring an additional 7,183 shares in the last quarter. Advisory Services Network LLC acquired a new stake in shares of Compass Pathways in the third quarter valued at approximately $41,000. Finally, North Star Investment Management Corp. raised its holdings in shares of Compass Pathways by 1,354.0% in the first quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after purchasing an additional 7,000 shares during the last quarter. 46.19% of the stock is currently owned by institutional investors and hedge funds.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.